Compare Amphastar Pharmaceuticals Inc (AMPH) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Under Armour Inc Class A trades at $6.72 (market cap $2.86B). The key difference: Under Armour Inc Class A is far larger — about 3.5× Amphastar Pharmaceuticals Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | UAA | |
|---|---|---|
Market Cap | $826.08M | $2.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $8.14 |
52-Week Low | $16.87 | $4.17 |
Enterprise Value | $1.22B | $4.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Under Armour (UAA) trades at $6.79, up 3.03% today, showing technical bullish momentum with moving averages supporting upward movement. However, the company faces fundamental challenges with negative net income margins (-9.98%) and declining revenue from $5.7B in 2024 to $5.2B in 2025. Recent earnings showed mixed results with a Q1 2026 miss, while cash flow remains negative at -$362M for 2025. The Dodge collaboration and Persona AI partnership represent strategic initiatives amid ongoing North American market weakness.
The outlook remains cautious with analyst consensus price target at $5.96 below current levels, reflecting concerns about profitability and revenue trends. Investment opportunity exists if international growth and cost management improve margins, but risks include persistent North American weakness, margin pressure, and negative cash flow generation. Wall Street sentiment leans neutral with 58% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
